Diagnostic role of complete blood count in pleural effusions

Pleural effusion (PE) can be seen during the course and treatment of many malignant or benign diseases. Congestive heart failure and pneumonia are the most common causes of benign pleural effusion (BPE), while lung and breast cancer are the most common causes of malignant pleural effusion (MPE). MPE indicates that the disease is extensive or advanced and the average survival is 4-12 months. In this study, we aimed to investigate the changes in complete blood count parameters in patients with benign and malignant PE. Patients who underwent thoracentesis and pleural fluid analysis between January 1, 2015 and December 1, 2020 were included in the study. Demographic characteristics, pathological diagnoses, pleural fluid cell analysis, blood parameters of the patients were recorded. The patients were divided into two groups according to their MPE and BPE detection status. Complete blood count parameters, Systemic Inflammatory Index (SII), Platelet / Lymphocyte Ratio (PLR), Monosin / Lymphocyte Ratio (MLR), Eosinophil / Lymphocyte Ratio (ELR) and Neutrophil / Lymphocyte Ratio (NLR) values were found in both groups and were recorded and compared. 240 patients with PE and meeting the study criteria were included in the study. There were 154 (64.17%) patients with BPE and 86 (35.83%) patients with MPE. In patients with MPE, WBC (103 / mL) 10.22 (2.32-27.50) (p = 0.001), Neutrophil (103 / UL) 8 (0.48-24.25) (p

PDF

___

Roberts ME, Neville E, Berrisford RG, et al. BTS pleural disease guideline group. management of a malignant pleural effusion: british thoracic society pleural disease guideline 2010. Thorax. 2010;65:ii32-40.
Clive AO, Kahan BC, Hooper CE, et al. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax. 2014;69:1098–104.
Bechara R, Ernst A. Medical evaluation of non-malignant pleural effusions. In: Sugarbaker D.J, Bueno R. Translation editors Yüksel M. Topçu S. Adult Thoracic Surgery. Nobel Medical Bookstores, 2011, p. 914.
Çobanoğlu U, Kızıltan R, Kemik Ö. Malignant pleural effusions: diagnosis and treatment. Van Tıp Derg. 2017;24:397-403.
Miserocchi G. Mechanisms controlling the volume of pleural fluid and extravascular lung water. Eur Respir Rev. 2009;18:244–52.
Jany B, Welte T. Pleural effusion in adults—etiology, diagnosis, and treatment. deutsches ärzteblatt international. continuing medical education. Dtsch Arztebl Int. 2019;116:377–86.
Esendağlı D, Maden E. Pleural effusion due to systemic diseases. Güncel Göğüs Hastalıkları Serisi. 2015;3:402-8.
Teke T. The new biomarkers for diagnosis of pleural effusions and differentation transudate-exudate. Güncel Göğüs Hastalıkları Serisi. 2015;3:291-315.
Light RW, Macgregor MI, Luchsinger PC, et al. Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med. 1972;77:507-13. 10. Ozsu S, Oztuna F, Mentese A, et al. Diagnostic value of suPAR in differentiating noncardiac pleural effusions from cardiac pleural effusions. Clin Respir J 2014. 11. Sahn SA, Huggins JT, San Jose E, et al. The art of pleural fluid analysis. Clin Pulm Med. 2013;20:77. 12. Lim JU, Yeo CD, Kang et al. Prognostic value of platelet count and lymphocyte to monocyte ratio combination in stage IV non-small cell lung cancer with malignant pleural effusion. PLOS ONE Published: July 13, 2018. 13. Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A, et al. Prognostic role of neutrophil-tolymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106:dju124.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.
Teramukai S, Kitano T, Kishida Y, et al. Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan multinational trial organisation LC00-03. Eur J Cancer. 2009;45:1950–8.
Sivrice ME, Okur E, Yasan H, et al. Can the systemic immune infammation index preoperatively predict nasal polyp subtypes? European Archives of Oto-Rhino-Laryngology 2020;277:3045–50.
Paramanathan A, Saxena A, Morris DL. A systematic review and metaanalysis on the impact of pre-operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours. Surg Oncol. 2014;23:31–9.
Guthrie GJ, Charles KA, Roxburgh CS, et al. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013;88:218–30.
Felding-Habermann B, O’Toole TE, Smith JW, et al. Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci U S A. 2001;98:1853–8.
Toda M, Tsukioka T, Izumi N, et al. Platelet-to-lymphocyte ratio predicts the prognosis of patients with non-small cell lung cancer treated with surgery and postoperative adjuvant chemotherapy. Thoracic Cancer. 2018;9:112–9.
Holgersson G, Bergstrom S, Hallqvist A, et al. The prognostic value of pretreatment thrombocytosis in two cohorts of patients with non-small cell lung cancer treated with curatively intended chemoradiotherapy. Neoplasma. 2017;64:909–15.
Coffelt SB, Hughes R, Lewis CE. Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochim Biophys Acta. 2009;1796:11–8.
Guruvayoorappan C. Tumor versus tumor-associated macrophages: how hot is the link? Integr Cancer Ther. 2008;7:90–5.
Siveen KS, Kuttan G. Role of macrophages in tumour progression. Immunol Lett. 2009;123:97–102.
Nam HS. Malignant pleural effusion: medical approaches for diagnosis and management. Tuberc Respir Dis (Seoul). 2014;76:211–7.